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Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)—
the one EBV antigen that is expressed in all EBV-
associated malignancies—has long been thought to
go undetected by the cell-mediated immune system.
However, recent studies show that EBNA1 can be
presented to both CD4
 
 
 
 and CD8
 
 
 
 T cells, making
it a potential new target for immunotherapy of EBV-
related cancers.
 
EBV, which infects 
 
 
 
90% of the human adult popula-
tion, is considered to be the classic example for immune
surveillance of persistent viral infections in humans (1). The
virus establishes life-long latency in memory B cells (2).
Different EBV latency programs are associated with many
important tumors, like Hodgkin’s disease and nasopharyn-
geal carcinoma, and also the EBV-transformed B cell lines
(lymphoblastoid cell lines [LCLs]) that are so often used in
human immunological research (3). Despite its significant
transforming capacity, EBV causes tumors only in a small
subset of infected individuals and is under effective immune
control in most EBV carriers (4). In this respect, EBV is
quite the opposite of HIV, which after establishing life-long
latency in memory T cells is controlled only in a small sub-
set of infected individuals, the so-called long-term non-
progressors, and causes AIDS in most infected individuals.
Understanding the mechanisms of EBV-specific immune
control might lead to the identification of crucial principles of
immune surveillance failing in other persistent viral infections.
 
EBNA1 Maintains EBV Latency in Proliferating Cells.
 
EBV DNA only infrequently integrates into the host cell
genome and is usually carried as circular DNA or episomes
in latently infected cells (5). Therefore, EBV requires a
mechanism for replicating viral DNA before mitosis and
distributing episomes into progeny cells during cell division.
EBNA1 fulfills these tasks by initiating replication through
binding to the episome with its COOH-terminal domain
and then cross-linking the episome to mitotic chromosomes
as a protein anchor (3). Therefore, EBNA1 is expressed in
all EBV-associated tumors (4) and EBV-positive proliferating
cells in healthy EBV carriers (6). Expression of all other
EBV-latent antigens can be absent in EBV
 
 
 
 tumors, like
Burkitt’s lymphoma, and in EBV
 
 
 
-replicating memory B
cells. These features would make EBNA1 a potential tumor
rejection antigen for EBV-associated malignancies and a
target for EBV immune control in asymptomatic carriers.
However, since Burkitt’s lymphoma cells, which express
EBNA1 as their only EBV latency antigen, are poorly
immunogenic (7) and only EBNA1 and LMP2A mRNAs
are detected in peripheral blood B cells (8), it has been
assumed that EBV persists in this EBNA1-only latency
program without detection by the immune system (8).
 
Immune Escape by EBNA1.
 
The idea that EBNA1 is
immunologically invisible was enforced by several studies,
which indicated that EBNA1 escapes recognition by cytotoxic
T cells. EBNA1 contains a Gly-Ala repeat domain which
was found to prevent antigen processing for cytolytic
CD8
 
 
 
 T cell recognition (9). Presence of this Gly-Ala
repeat domain in EBNA1 prevents processing by the
proteasome, the main catalytic machinery for the gen-
eration of MHC class I ligands and therefore CD8
 
 
 
 T
cell epitopes (10). More recently, the very same domain
was found to prevent 
 
EBNA1
 
 mRNA translation, and
this effect alone diminishes CD8
 
 
 
 T cell recognition of
EBNA1 by 
 
 
 
30% (11).
 
EBV Persistence without EBNA1.
 
The view that the
EBNA1-only latency program ensures EBV persistence in
healthy EBV carriers was first challenged by D. Thorley-
Lawson and colleagues who found that EBV persists mainly
in peripheral memory B cells without expression of any
EBV-latent antigen (2). These long-lived memory B cells
need to express EBNA1 only occasionally during homeo-
static proliferation with 
 
 
 
1% of EBV-positive memory B
cells containing EBNA1 at any given time point (6).
These studies suggested that EBV does not rely on
EBNA1 immune escape for its persistence but uses long-
lived memory B cells without detectable viral antigen
expression to persist life-long in healthy EBV carriers.
Therefore, EBV persistence and immune recognition of
EBNA1 do not exclude each other.
 
CD4
 
 
 
 T Cell Recognition of EBNA1.
 
The idea that
EBNA1 is immunologically invisible was first challenged
when EBV-specific CD4
 
 
 
 T cell responses were examined.
Although initially only one EBNA1-specific CD4
 
 
 
 T cell
clone was characterized (12), in more recent studies nearly
all healthy EBV carriers were found to mount a CD4
 
 
 
 T cell
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response to this antigen (13, 14). Moreover, EBNA1 was
recognized in more EBV-infected individuals than any other
EBV-latent antigen (13). EBNA1-specific CD4
 
 
 
 T cell re-
sponses were found to be mainly T helper type 1 in nature
(15) and could directly recognize LCLs (13, 15), Burkitt’s
lymphoma cells (16, 17), and freshly EBV-transformed B
cells (18). Therefore, EBNA1-specific CD4
 
 
 
 T cells might
orchestrate and maintain EBV-specific immune control and
serve as effectors against EBV-associated malignancies.
 
CD8
 
 
 
 T Cell Recognition of EBNA1.
 
The volte-face
that places EBNA1 as potentially relevant antigen in EBV-
specific immune control is now completed with two arti-
cles in this issue (20–21) and a study that appeared earlier
this year in the February 2nd issue of the 
 
JEM
 
 (19). These
studies document the recognition of EBV-transformed B
cells by EBNA1-specific CD8
 
 
 
 T cells. All three studies
utilize IFN-
 
 
 
 secretion as the assay for T cell recognition of
EBNA1, and two reports demonstrate moderate cytotoxic-
ity against LCLs (19, 21). Importantly, these EBNA1-spe-
cific CD8
 
 
 
 T cells are able to suppress LCL outgrowth in
vitro (20). The data suggest that IFN-
 
 
 
 release, and proba-
bly to a lesser extent cytotoxicity, inhibit growth of EBV-
transformed B cells. This is consistent with an earlier report
in which CD8
 
 
 
 T cells could control the outgrowth of
EBV-transformed B cells solely by IFN-
 
 
 
 secretion (22).
How do these new findings fit with the earlier descrip-
tions of Gly-Ala repeat domain–mediated inhibition of
EBNA1 recognition by CD8
 
 
 
 T cells? Lee et al. report that
the Gly-Ala repeat domain reduces CD8
 
 
 
 T cell recogni-
tion of EBNA1 by a factor of four. This implies that recog-
nition of full-length EBNA1 in LCLs is barely above the
detection limit in classical cytotoxicity assays that have been
used in previous studies (20). However, with more sensi-
tive IFN-
 
 
 
 detection assays LCL recognition by EBNA1–
specific CD8
 
 
 
 T cells can be documented, and this seems
sufficient to control EBV-transformed B cells with the ex-
ception of Burkitt’s lymphoma, which has a more general
defect in MHC class I antigen processing (7).
 
Processing of EBNA1 for Presentation on MHC Class I.
 
The three 
 
JEM
 
 papers on EBNA1-specific CD8
 
 
 
 T cells
(19–21) also contain interesting information on the antigen
processing and degradation of EBNA1. It was noted earlier
that full-length EBNA1 is very stable with a half-life 
 
 
 
20 h
in B cell lines (10), but deletion of the Gly-Ala repeat do-
main (
 
 
 
GA) lowers EBNA1’s half-life substantially (23).
Degradation of the short-lived EBNA1
 
 
 
GA variant is pro-
teasome dependent, whereas the degradation of long-lived
full-length EBNA1 is proteasome independent (10). In the
study by Tellam et al., the authors demonstrate that the
half-life of full-length EBNA1 depends on the cellular
background: it is reduced to 4 h in primary epithelial cell
lines, but EBNA1 degradation remains insensitive to pro-
teasome inhibition as in EBV-transformed B cells (21). By
contrast, in all three studies CD8
 
 
 
 T cell recognition is in-
hibited by various proteasome inhibitors (19–21). These
data suggest that EBNA1-derived CD8
 
 
 
 T cell epitopes
are not derived from full-length EBNA1 but from pro-
teins that are prematurely truncated during translation or
mal-folded after translation (known as defective ribosomal
products or DRiPs). These DRiPs are preferentially de-
graded by proteasomes for MHC class I presentation (Fig.
1) (24). Indeed, Voo et al. showed that CD8
 
 
 
 T cell recog-
Figure 1. Suggested antigen processing pathways of
EBNA1. (A) Defective ribosomal products (DRiPs) of
EBNA1 are degraded by the proteasome for MHC class I
presentation (endogenous MHC class I antigen processing).
(B) Full-length EBNA1 is not degraded by the proteasome
and might be the source of MHC class II ligands (en-
dogenous MHC class II antigen processing). (C) EBNA1
released by dying EBV-transformed B cells is taken up by
APCs and presented for CD4  and CD8  T cell priming
(exogenous MHC class I and II antigen processing). 
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nition of EBNA1 can be rapidly blocked by ementine, an
irreversible inhibitor of protein biosynthesis (19). Along
the same lines, Tellam et al. report that they can block
EBNA1-specific CD8
 
 
 
 T cell recognition of LCLs by an-
other protein biosynthesis inhibitor, cyclohexamide (21).
Since, most EBNA1-derived CD8
 
 
 
 T cell epitopes are
COOH-terminal of the Gly-Ala repeat domain, the ques-
tion remains why this domain cannot prevent DRiP degra-
dation by the proteasome. The study by Voo et al. offers a
possible answer to this dilemma. They report that EBNA1-
derived CD8
 
 
 
 T cell epitope presentation is not only de-
pendent on proteasome-mediated proteolysis but also on
serine protease degradation (19). Preprocessing of DRiPs
by a serine protease could separate the CD8
 
 
 
 T cell epitopes
from the Gly-Ala repeat domain and make them accessible
for proteasome degradation.
 
Processing of EBNA1 for Presentation on MHC Class II.
 
Although full-length EBNA1 is not processed for MHC
class I presentation, it might be vital for MHC class II pre-
sentation (Fig. 1). Two main processing pathways can be
envisioned for EBNA1 delivery for MHC class II presenta-
tion. Full-length EBNA1 could gain access to the MHC
class II loading compartment from within the cell, e.g., by
autophagy, and sensitize EBV-associated tumor cells for
CD4
 
 
 
 T cell recognition. Alternatively, EBNA1 from dy-
ing cells could be taken up by bystander cells and processed
for presentation on MHC class II. This latter cross-presen-
tation pathway seems crucial for the priming of EBV-spe-
cific immune control by DCs in vitro (25), but this path-
way remains to be demonstrated in EBV
 
 
 
 lymphoma cells.
Extracellular EBNA1 is also necessary for EBNA1-specific
antibody responses, which can be seen in all healthy EBV
carriers (26), and these antibodies could also facilitate EBNA1
cross-presentation (27). The fate of full-length EBNA1 and
its connection to MHC class II presentation remains a chal-
lenge for future studies.
 
The Relevance of EBNA1 for EBV Immune Surveillance.
 
The observations on the recognition of EBNA1 have
moved this latency antigen back into the focus of research
on EBV immune surveillance. EBNA1, the one EBV la-
tency antigen that is expressed in all EBV-associated malig-
nancies and maintains EBV DNA in proliferating cells,
might prove to be the Achilles heel of these tumors. It is
now evident that EBNA1 can elicit Th1-type CD4
 
 
 
 and
effector CD8
 
 
 
 T cells in healthy EBV carriers. In fu-
ture  studies, these responses need to be compared with
EBNA1-specific T cell responses in patients with EBV-
associated malignancies. The response to EBNA1 and other
EBV antigens needs to be better charted in blood and lym-
phoid tissues of both healthy carriers and patients with tu-
mors. Along these lines, the frequency of EBNA1-specific
CD8
 
 
 
 T cell responses and if EBNA1-specific CD4
 
 
 
 and
CD8
 
 
 
 T cell responses are altered in situations of EBV-
associated malignancies remains to be determined.
 
The Potential of EBNA1 for Immunotherapy of EBV-associ-
ated Malignancies.
 
A more demanding proof of principle
would entail EBNA1-based immunizations of patients with
EBV
 
 
 
 tumors to determine if EBNA1 is indeed a key
antigen in EBV-specific immune control. Passive and ac-
tive immunotherapies have indeed been successful against
EBV-associated malignancies. Adoptive transfer of autolo-
gous EBV-specific T cell populations into bone marrow
transplant patients curbed the uncontrolled outgrowth of
EBV-transformed B cells, known as lymphoproliferative
disease (28). Since antigenic specificities of the transferred
T cell lines were not determined, EBNA1-specific CD4
 
 
 
and CD8
 
 
 
 T cells might have contributed to the success of
this immunotherapy. In addition, vaccination with EBV la-
tent antigens has been attempted in nasopharyngeal carci-
noma patients (29). For this purpose, DCs, loaded with
CD8
 
 
 
 T cell epitopes of the latent membrane protein 2
(LMP2) of EBV, were injected into inguinal lymph nodes
of nasopharyngeal carcinoma patients. LMP2 is one of the
two other EBV proteins expressed in nasopharyngeal carci-
noma apart from EBNA1 (4). However, only 9 of 16 pa-
tients showed transiently increased LMP2-specific CD8
 
 
 
 T
cell responses and only 2 of these experienced partial tumor
regression with stable disease in only 1 patient (29). The in-
vestigators concluded that future vaccination approaches
should aim to elicit sustained T cell responses and should
stimulate both EBV-specific CD4
 
 
 
 and CD8
 
 
 
 T cells.
Therefore, the same group has developed a recombi-
nant modified vaccinia virus Ankara encoding an EBNA1–
LMP2 fusion protein and proposes to elicit EBNA1-spe-
cific CD4
 
 
 
 and LMP2-specific CD8
 
 
 
 T cell responses in
nasopharyngeal carcinoma patients (30). Since EBNA1 has
now been shown to mediate protection against EBV-trans-
formed B cells in vitro, more immunotherapies with this
promising CD4
 
 
 
 and CD8
 
 
 
 T cell antigen should be de-
veloped to target EBV-associated malignancies.
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